Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Medical guidelines

Vol. 153 No. 8 (2023)

Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer

  • Arnoud J. Templeton
  • Aurelius Omlin
  • Dominik Berthold
  • Jörg Beyer
  • Irene A. Burger
  • Daniel Eberli
  • Daniel Engeler
  • Christian Fankhauser
  • Stefanie Fischer
  • Silke Gillessen
  • Guillaume Nicolas
  • Stephanie Kroeze
  • Anja Lorch
  • Michael Müntener
  • Alexandros Papachristofilou
  • Niklaus Schaefer
  • Daniel Seiler
  • Frank Stenner
  • Petros Tsantoulis
  • Tatjana Vlajnic
  • Thomas Zilli
  • Daniel Zwahlen
  • Richard Cathomas
DOI
https://doi.org/10.57187/smw.2023.40108
Cite this as:
Swiss Med Wkly. 2023;153:40108
Published
15.08.2023

Summary

The management of prostate cancer is undergoing rapid changes in all disease settings. Novel imaging tools for diagnosis have been introduced, and the treatment of high-risk localized, locally advanced and metastatic disease has changed considerably in recent years. From clinical and health-economic perspectives, a rational and optimal use of the available options is of the utmost importance. While international guidelines list relevant pivotal trials and give recommendations for a variety of clinical scenarios, there is much room for interpretation, and several important questions remain highly debated. The goal of developing a national consensus on the use of these novel diagnostic and therapeutic strategies in order to improve disease management and eventually patient outcomes has prompted a Swiss consensus meeting. Experts from several specialties, including urology, medical oncology, radiation oncology, pathology and nuclear medicine, discussed and voted on questions of the current most important areas of uncertainty, including the staging and treatment of high-risk localized disease, treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and use of new options to treat metastatic castration-resistant prostate cancer (mCRPC).

References

  1. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2022.
  2. Ingvar J, Hvittfeldt E, Trägårdh E, Simoulis A, Bjartell A. Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res. 2022 Aug;12(1):48. 10.1186/s13550-022-00918-7 DOI: https://doi.org/10.1186/s13550-022-00918-7
  3. Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2021 Aug;4(4):635–44. 10.1016/j.euo.2020.06.012 DOI: https://doi.org/10.1016/j.euo.2020.06.012
  4. Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4483–94. 10.1007/s00259-021-05424-x DOI: https://doi.org/10.1007/s00259-021-05424-x
  5. Vollnberg B, Alberts I, Genitsch V, Rominger A, Afshar-Oromieh A. Assessment of malignancy and PSMA expression of uncertain bone foci in [18F]PSMA-1007 PET/CT for prostate cancer-a single-centre experience of PET-guided biopsies. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3910–6. 10.1007/s00259-022-05745-5 DOI: https://doi.org/10.1007/s00259-022-05745-5
  6. Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al.; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022 Jan;399(10323):447–60. 10.1016/S0140-6736(21)02437-5
  7. Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). Annals of Oncology 2022;33 (suppl_7):S808-S69. 10.1016/annonc/annonc89 (LBA 9). DOI: https://doi.org/10.1016/j.annonc.2022.08.064
  8. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021 Feb;7(1):9. 10.1038/s41572-020-00243-0 DOI: https://doi.org/10.1038/s41572-020-00243-0
  9. Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate. 2018 Sep;78(12):889–95. 10.1002/pros.23645 DOI: https://doi.org/10.1002/pros.23645
  10. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug;373(8):737–46. 10.1056/NEJMoa1503747 DOI: https://doi.org/10.1056/NEJMoa1503747
  11. Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018 Jun;73(6):847–55. 10.1016/j.eururo.2018.02.001 DOI: https://doi.org/10.1016/j.eururo.2018.02.001
  12. Cornford P, van den Bergh RC, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021 Feb;79(2):263–82. 10.1016/j.eururo.2020.09.046 DOI: https://doi.org/10.1016/j.eururo.2020.09.046
  13. Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al.; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design. Lancet. 2022 Apr;399(10336):1695–707. 10.1016/S0140-6736(22)00367-1 DOI: https://doi.org/10.1016/S0140-6736(22)00367-1
  14. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al.; ARASENS Trial Investigators. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022 Mar;386(12):1132–42. 10.1056/NEJMoa2119115
  15. Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023 Jul;41(20):3595–607. 10.1200/JCO.23.00041 DOI: https://doi.org/10.1200/JCO.23.00041
  16. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al.; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec;392(10162):2353–66. 10.1016/S0140-6736(18)32486-3
  17. de Bono JS, Chowdhury S, Feyerabend S, Elliott T, Grande E, Melhem-Bertrandt A, et al. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. Eur Urol. 2018 Jul;74(1):37–45. 10.1016/j.eururo.2017.07.035 DOI: https://doi.org/10.1016/j.eururo.2017.07.035
  18. Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R, et al.; PLATO collaborators. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018 Sep;36(25):2639–46. 10.1200/JCO.2018.77.9827 DOI: https://doi.org/10.1200/JCO.2018.77.9827
  19. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May;161(5):1215–28. 10.1016/j.cell.2015.05.001
  20. de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May;382(22):2091–102. 10.1056/NEJMoa1911440 DOI: https://doi.org/10.1056/NEJMoa1911440
  21. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evid. 2022;2022(9):1. 10.1056/EVIDoa2200043 DOI: https://doi.org/10.1056/EVIDoa2200043
  22. Chi KN, Rathkopf DE, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Journal/ASCO GU abstract #12 2022; DOI: https://doi.org/10.1200/JCO.2022.40.6_suppl.012
  23. Pfizer. Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial 2022 (Press release on Oct 4);
  24. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al.; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep;385(12):1091–103. 10.1056/NEJMoa2107322 DOI: https://doi.org/10.1056/NEJMoa2107322

Most read articles by the same author(s)

<< < 1 2